An FDA-approved nasal spray for depression that hasn't responded to standard antidepressants — administered in-office under physician supervision.
Spravato (esketamine) is for patients who have tried multiple antidepressants without adequate relief. Unlike a pill you take at home, it's a monitored nasal spray given in our Portsmouth office, with Dr. Schopick overseeing the session from start to finish.
Many patients come to Spravato after months or years of trying different medication combinations. For some, it offers a meaningfully different mechanism of action — and for patients with treatment-resistant depression, that can matter.
Coverage is typically available for patients who meet treatment-resistant depression criteria — usually two or more failed antidepressant trials. We help verify your plan and handle prior authorization. The REMS copay assistance program may also reduce out-of-pocket cost for eligible patients.
Sessions typically start twice weekly for the first month, then taper based on how you respond. Dr. Schopick adjusts the schedule to your individual course of treatment.
No. Spravato® requires monitored observation after dosing, and you'll need to arrange a ride home in advance — you cannot drive yourself the day of treatment. If that's a barrier, Deep TMS may be worth discussing instead.
REMS (Risk Evaluation and Mitigation Strategy) is the FDA-required safety program for Spravato®, which includes in-office monitoring and may include copay assistance for eligible patients.